In our cases, we decided to give sirolimus to improve hypoglycemia in a patient with AKT2 mutation and another patient with PTHS as sirolimus will inhibit mTOR, the next downstream step in PTEN/AKT signalling. Here, AKT2 is linked to Pitt-Hopkins syndrome.